Abstract
Patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis. Encorafenib, binimetinib, and cetuximab (triplet-therapy) became the latest approach for targeting therapy of V600E-mutated mCRC. However, the clinical courses and complications of the combination therapy are still unknown in clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
